By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today said that revenues for full-year 2011 dipped 22 percent year over year.

For 2011, the German molecular diagnostics company saw revenues of €1.4 million ($1.9 million) compared to €1.8 million a year ago, a drop-off that Epigenomics attributed to a decline in collaborative income. Sales of its Epi proColon tests were up 38 percent year over year in Europe, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.